• Explore /
  • Poster
  • / Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC).

Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC).

Abstract Poster

Authors

Chiara Mercinelli

Chiara Mercinelli

Medical Oncology Department, IRCCS San Raffaele Hospital, Milan, Italy

Chiara Mercinelli , Daniele Raggi , Antonio Cigliola , Valentina Tateo , Damiano Alfio Patanè , Emanuele Crupi , Maurizio Colecchia , Marco Moschini , Chiara Re , Giulio Avesani , Alberto Briganti , Francesco Montorsi , Jeffrey S. Ross , Ryon Graf , Dean C. Pavlick , Andrea Necchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 653)

DOI

10.1200/JCO.2024.42.4_suppl.653

Abstract #

653

Poster Bd #

J17

Abstract Disclosures

Similar Posters

First Author: Chiara Mercinelli

First Author: Ralph M. Wirtz

First Author: Andrea Necchi

Poster

2015 Genitourinary Cancers Symposium

Circulating tumor cells (CTC) as potential biomarkers in neoadjuvant chemotherapy of muscle invasive bladder cancer (MIBC).

Circulating tumor cells (CTC) as potential biomarkers in neoadjuvant chemotherapy of muscle invasive bladder cancer (MIBC).

First Author: Ajjai Shivaram Alva